V+PSF-M for Tobacco Cessation in HIV Care in India
Varenicline and Mobile Behavioral Assistance for Tobacco Cessation in HIV Care in India
University of Colorado, Denver
400 participants
Jan 2, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV). The study interventions used in this research study are: * Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program) * Varenicline (or Chantix, apovarenicline, Champix or Nocrav)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Per package dosing, tablet taken orally
Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
Brief cessation advice plus referral to local tobacco quitline
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05786547